Latest News
Novartis Presents New Zolgensma® Data Further Demonstrating Therapeutic Benefit
Novartis Gene Therapies today announced new interim data from the ongoing Phase 3 STR1VE-EU clinical trial for Zolgensma® (onasemnogene abeparvovec). The data demonstrates that patients with spinal muscular […]
Read More ›Genentech Presents New 2-Year Data for Evrysdi (risdiplam) in Infants with Type 1 SMA
Genentech, a member of the Roche Group, today announced new 2-year data from Part 1 of the pivotal FIREFISH study of Evrysdi™ (risdiplam) in infants aged 2-7 months with symptomatic […]
Read More ›Community Spotlight: Xavier and Rose’s SMA Diagnosis
Carrie Menke is a South Dakota native who resides in Sioux Falls with her husband Tony and their four children — Xavier, Colette, Avila, and Rose. Carrie is one of […]
Read More ›Novartis Issues Community Statement with Update on AVXS-101 Intrathecal Clinical Development Program
Dear SMA Community, We recently received important feedback from the U.S. Food and Drug Administration (FDA) following their review of data from the STRONG study of AVXS-101 intrathecal (IT) formulation […]
Read More ›Team Biogen Runs Over 22,000 Miles During SMA Awareness Month
Team Biogen hit the ground running throughout the month of August in honor of SMA Awareness Month. Together, the team logged 22,059 miles collectively from August […]
Read More ›Community Spotlight: Braedon’s Newborn Screening Diagnosis
September is Newborn Screening Awareness Month, a chance to talk about the progress we have made in getting spinal muscular atrophy (SMA) added to newborn screening panels and the work […]
Read More ›